Visão geral da empresa
A clinical-stage pharmaceutical entity, Q/C Technologies, Inc. concentrates its operational efforts on the development and commercialization of therapeutic platforms designed to target specific biological mechanisms for treating autoimmune diseases. Within the broader financial landscape, the firm operates in the Technology sector, specifically categorized under the Computer Hardware industry, a classification that reflects its current market listing despite its primary focus on pharmaceutical research and development. The company maintains a market capitalization of $27.02M and employs a workforce of 2 individuals, while annual revenue figures are not currently available for reporting in the public financial data. These valuation metrics indicate that the company functions as a small-cap entity with limited current revenue generation, suggesting that its market value is derived primarily from potential future clinical outcomes rather than established commercial sales streams.
Saúde financeira
The company's financial statements reveal a Net Income of $-11,559,973 over the trailing twelve months, while both Revenue and EBITDA are listed as N/A, indicating that the gap between nominal revenue and significant net losses points to substantial operating costs or early-stage research expenditures that exceed current income generation. The Free Cash Flow stands at $-6,374,298, which signifies a high capital requirement for ongoing operations and suggests that the company currently lacks the financial flexibility to fund expansion without external capital injections or equity dilution. All three profitability metrics—Gross Margin, Operating Margin, and Profit Margin—are reported as 0.0%, a figure that indicates the company has not yet achieved positive profitability and that its financial structure is still in the phase of loss accumulation typical of clinical-stage ventures. Regarding the balance sheet, the company holds $10.00M in cash against $0 in debt, resulting in a Debt to Equity ratio of N/A, which portrays a conservative capital structure with no leverage to offset against current liabilities. The Current Ratio is 1.71, a metric that demonstrates the company possesses sufficient short-term liquid assets to cover its immediate obligations without relying on debt restructuring or asset sales. Furthermore, the Return on Equity is -40.6% and the Return on Assets is -16.4%, metrics that reveal that management has not yet generated returns on the capital invested by shareholders or utilized in asset acquisition, highlighting the early nature of the investment lifecycle.
Avaliação de valorização
Valuation multiples for Q/C Technologies, Inc. show a P/E Ratio (TTM) of N/A and a Forward P/E of N/A, implying that traditional earnings-based valuation models cannot be applied due to the absence of positive earnings, which prevents any meaningful comparison between trailing and forward expectations. The Price to Book ratio is 0.72, suggesting that the market values the company at a discount to its net book value, a scenario often seen in distressed or early-stage biotech firms where future prospects are highly uncertain. Alternative valuation metrics such as Price to Sales and EV/EBITDA are also N/A, indicating that the market is not pricing the stock based on revenue efficiency or enterprise value multiples relative to earnings, but rather on asset backing or potential option value. The stock has exhibited significant volatility, trading between a 52-Week High of $44.40 and a 52-Week Low of $2.50, meaning the current price position fluctuates widely within this broad range relative to the historical extremes. The Beta of 2.23 indicates that the stock's price volatility is more than twice that of the broader market, reflecting the high risk profile associated with clinical-stage investments and the sensitivity of the price to general market movements.
Growth & Income
Growth metrics for the company are not yet established, as both Revenue Growth (YoY) and Earnings Growth (YoY) are listed as N/A, which means there is no historical data to determine if earnings are growing faster or slower than revenue. As a non-dividend payer, the company reports a Dividend Yield of N/A and a Payout Ratio of 0.0%, confirming that the firm does not distribute cash to shareholders and instead retains all available cash reserves to fund its research and development activities. Since the company does not pay dividends, the implicit growth strategy involves reinvesting earnings—or in this case, burning cash reserves—to advance clinical trials and secure regulatory approval for its therapeutic platforms. The overall growth and income profile is characterized by a complete lack of current income distribution and unquantified growth rates, placing the entire investment thesis on the potential for future commercialization of the Isomyosamine therapeutic target rather than current financial performance or dividend yield.